Research Article
Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France
Table 5
Estimated health care costs related to treatment of advanced STSa in Spain ().
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SD = standard deviation. Note: systemic treatment administration costs include the costs of administration and the costs of outpatient visits or hospitalizations that were for chemotherapy administration. Treatment-related adverse event costs include costs associated with growth factors (which were assumed to have been used to prevent and/or treat neutropenia or anemia) and costs associated with hospitalizations to manage toxicities/side effects related to treatments or procedures. For systemic treatment costs by line of therapy, costs are reported among those patients who received each line of therapy. Costs for all patients are reported by line of therapy, but costs for those using specific treatment regimens are not provided for third- and fourth-line patients due to small sample sizes. aCosts are in 2016 euros and were inflated when necessary using the indice de precios de consumo, medicina [28]. bOne patient with dactinomycin use was excluded from this analysis. cSystemic treatment administration costs include the costs of administration, as well as the costs of outpatient visits or hospitalizations that were for chemotherapy administration. dCosts are reported among those patients who received each line of therapy. eTreatment-related adverse event costs include costs associated with growth factors (which were assumed to have been used to prevent and/or treat neutropenia or anemia), as well as costs associated with hospitalizations to manage toxicities/side effects related to treatments or procedures. fOther direct health care costs include costs unrelated to anticancer therapy (i.e., other direct health care costs exclude costs associated with anticancer drug acquisition and administration and treatment-related adverse events). These other direct health care costs include costs associated with outpatient visits, accident and emergency visits, inpatient hospitalizations, inpatient long-term care and hospice care, and supportive care. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||